NeuroPace (NASDAQ:NPCE – Get Rating) and MeaTech 3D (OTCMKTS:MTTCF – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.
This is a summary of recent ratings for NeuroPace and MeaTech 3D, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider & Institutional Ownership
77.6% of NeuroPace shares are held by institutional investors. 10.4% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares NeuroPace and MeaTech 3D’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares NeuroPace and MeaTech 3D’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NeuroPace||$45.18 million||2.74||-$36.08 million||($1.73)||-2.91|
MeaTech 3D has lower revenue, but higher earnings than NeuroPace.
NeuroPace beats MeaTech 3D on 5 of the 8 factors compared between the two stocks.
About NeuroPace (Get Rating)
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
About MeaTech 3D (Get Rating)
MeaTech 3D Ltd., a deep-tech food company, engages in the development of cultivated meat technologies to manufacture cultivated meat without animal slaughter. The company develops a three-dimensional bioprinter to deposit layers of differentiated stem cells, scaffolding, and cell nutrients in a three-dimensional form of structured cultured meat. It intends to license its production technology; provide associated products, such as cell lines, printheads, bioreactors, and incubators; and offer services, such as technology implementation, training, and engineering support directly and through contractors to food processing and food retail companies. The company is headquartered in Rehovot, Israel.
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.